FYB201 0.5 mg (0.05 mL of 10 mg/mL)
ApprovedCompleted 0 views this week 0 watching💤 Quiet
Interest: 33/100
33
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Age-Related Macular Degeneration
Conditions
Age-Related Macular Degeneration, Branch Retinal Vein Occlusion with Macular Edema, Central Retinal Vein Occlusion with Macular Edema
Trial Timeline
Jun 11, 2024 → Aug 8, 2024
NCT ID
NCT06708624About FYB201 0.5 mg (0.05 mL of 10 mg/mL)
FYB201 0.5 mg (0.05 mL of 10 mg/mL) is a approved stage product being developed by Formycon AG for Age-Related Macular Degeneration. The current trial status is completed. This product is registered under clinical trial identifier NCT06708624. Target conditions include Age-Related Macular Degeneration, Branch Retinal Vein Occlusion with Macular Edema, Central Retinal Vein Occlusion with Macular Edema.
What happened to similar drugs?
20 of 20 similar drugs in Age-Related Macular Degeneration were approved
Approved (20) Terminated (3) Active (0)
Hype Score Breakdown
Clinical
20
Activity
8
Company
5
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06708624 | Approved | Completed |
Competing Products
20 competing products in Age-Related Macular Degeneration